Quantum Leap Healthcare Collaborative

Agent Information Sheet

Widely hailed as the future of phase II drug development, the adaptive I-SPY 2 platform trial has set a new benchmark for
Close
Close
I-SPY Trial Manuscript
<- Back to All Agents

patritumab

Trade Name:
US-1287
Status:
Halted
Agent Chaperone(s):
Treatment Protocol:
Patritumab is a Anti-HER3 monoclonal antibody (mAb). Patritumab is administered intravenously at 18 mg/kg loading followed by 9 mg/kg thereafter once every 3 weeks (q3w), with weekly paclitaxel (q1w) at 80 mg/m2, and weekly trastuzumab (q1w) at 4 mg/kg (loading dose) and 2 mg/kg (thereafter) for 12 total weeks. This regimen is followed by AC (q2w or q3w) for 4 weeks.
Date Entered I-SPY:
September 22, 2016
Date Left I-SPY:
October 19, 2017
No. Participants in Arm:
31
Graduating Subtypes:
Agent Description:

Patritumab is an investigational fully human monoclonal antibody that inhibits HER3, a unique member of the HER family that is abnormally activated in several types of cancer.1,2 To stimulate growth of a cancer cell, the HER3 receptor binds (dimerizes) with another HER family receptor such as EGFR or HER2. 1, 2 Preclinical evidence suggests that the combination of a HER3 inhibitor with other inhibitors of HER family receptors may be a promising therapeutic approach in treating certain cancers

Notes:
Final pCR Probabilities:
Primary Manuscript:
 
abstractpdfdoi link